LXRX
Lexicon Pharmaceuticals·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 0
Consensus Rating "Strong Buy"
Revenue Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About LXRX
Lexicon Pharmaceuticals, Inc.
A company that developing small molecule compounds to treat diabetes and gastrointestinal disorders
Biological Technology
07/07/1995
04/07/2000
NASDAQ Stock Exchange
103
12-31
Common stock
2445 Technology Forest Blvd., 11th Floor , The Woodlands, TX 77381
--
Lexicon Pharmaceuticals, Inc., is a biopharmaceutical company focused on researching and achieving breakthroughs in the treatment of human diseases. Through gene knockout technology and a comprehensive platform of advanced medical technology, the company has systematically studied the physiological and behavioral functions of nearly 5,000 genes in mice, and evaluated the utility of proteins encoded by corresponding human genes as potential drug targets, and has identified and verified more than 100 targets in living (or living organisms) that can be well applied to drug discovery. For those targets that are identified as having high medicinal value, it is committed to the development of potential new drugs. The company was established in Delaware on July 7, 1995, and began operations in September 1995.
Earnings Call
Q2/2025
Estimate EPS-0.08
Actual EPS0.01
Estimate Revenue4.87M
Actual Revenue28.87M
Lexicon Pharmaceuticals’ Q2 2025: Navigating Contradictions in Trial Designs, Partnering Strategies, and Financial Guidance
Aug 06,2025 12:46
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
LXRX has released its 2025 Q3 earnings. EPS was reported at -0.04, versus the expected -0.07, beating expectations. The chart below visualizes how LXRX has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
LXRX has released its 2025 Q3 earnings report, with revenue of 14.18M, reflecting a YoY change of 710.40%, and net profit of -12.77M, showing a YoY change of 80.30%. The Sankey diagram below clearly presents LXRX's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
